Prognostic Value of Transcranial Doppler Ultrasound in the Clinical Evolution of Patients With Acute Ischemic Stroke. The TRADE-AIS Study

Launched by JOSE IVAN RODRIGUEZ DE MOLINA SERRANO · May 27, 2025

Keywords

ClinConnect Summary

The TRADE-AIS study is a clinical trial that aims to understand how certain measurements taken from a test called transcranial Doppler ultrasound (TCD) can help predict how well patients will recover after having an acute ischemic stroke, which is when blood flow to the brain is blocked. The study will look specifically at the flow of blood in a major brain artery and how this relates to improvements in the patient's neurological condition over a short period. It will also examine other factors that might influence recovery, such as the presence of alternative blood flow routes in the brain.

To participate in this study, individuals must be at least 18 years old and have been diagnosed with an acute ischemic stroke within the last 24 hours. They will need to undergo the TCD test within this timeframe and be able to provide consent for participation. It's important to note that individuals with certain conditions, like bleeding in the brain or severe neurological diseases, won't be eligible. Those who join the study can expect to undergo a TCD test and have their recovery monitored to see how well they improve after the stroke. The trial is not yet recruiting participants, but it aims to provide valuable insights into stroke recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Clinical diagnosis of acute ischemic stroke
• • Onset of symptoms ≤ 24 hours before admission
• • Underwent or will undergo transcranial Doppler ultrasound within 24 hours of symptom onset
• • Able to provide informed consent or consent obtained from a legal representative
• Exclusion Criteria:
• • Evidence of intracerebral hemorrhage on imaging
• • Inadequate temporal acoustic window for transcranial Doppler
• • Intubated or hemodynamically unstable prior to Doppler evaluation
• • Known diagnosis of neurodegenerative disease significantly affecting baseline neurological function (e.g., advanced dementia, Parkinson's disease)
• • Refusal to participate or withdrawal of consent